Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 16/20 | 0.42 |
| ▸ | MAOA | P21397 | 15/20 | 0.42 |
| ▸ | MAOB | P27338 | 15/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5321239 | 0.67 | NFKB1 (0.37) | TSHRKDM1AMAOAMAOBMEN1 | |
| SCHEMBL9055452 | 0.64 | TACR1 (0.38) | TSHRKDM1AMAOAMAOBMEN1 | |
| SCHEMBL10020901 | 0.64 | TACR1 (0.40) | TSHRKDM1AMAOAMAOBMEN1 | |
| SCHEMBL20377916 | 0.64 | TSHR (0.71) | TSHRKDM1AMAOAMAOBMEN1 | |
| SCHEMBL11216596 | 0.63 | KDM1A (0.48) | KDM1AMAOAMAOB | |
| SCHEMBL10409193 | 0.63 | NFKB1 (0.43) | TSHRKDM1AMAOAMAOBMEN1 | |
| SCHEMBL6883069 | 0.62 | MEN1 (0.43) | TSHRKDM1AMAOAMAOBMEN1 | |
| SCHEMBL6873760 | 0.62 | MEN1 (0.43) | TSHRKDM1AMAOAMAOBMEN1 | |
| SCHEMBL28580157 | 0.62 | KDM1A (0.43) | KDM1AMAOAMAOBMEN1CYP2C19 | |
| SCHEMBL6873757 | 0.62 | MEN1 (0.43) | TSHRKDM1AMAOAMAOBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687500-B2 | Substituted oxetanes, method of making, and method of use thereof | THE UNIVERSITY OF CONNECTICUT (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687500-B2 | Substituted oxetanes, method of making, and method of use thereof | THE UNIVERSITY OF CONNECTICUT (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687500-B2 | Substituted oxetanes, method of making, and method of use thereof | THE UNIVERSITY OF CONNECTICUT (US) | 2010-03-30 | — | — | US | disclosed |
| US-20080139566-A1 | SUBSTITUTED OXETANES, METHOD OF MAKING, AND METHOD OF USE THEREOF | HOWELL AMY R | 2008-06-12 | — | — | US | disclosed |
| US-20080139566-A1 | SUBSTITUTED OXETANES, METHOD OF MAKING, AND METHOD OF USE THEREOF | HOWELL AMY R | 2008-06-12 | — | — | US | disclosed |
| US-20080139566-A1 | SUBSTITUTED OXETANES, METHOD OF MAKING, AND METHOD OF USE THEREOF | HOWELL AMY R | 2008-06-12 | — | — | US | disclosed |
| US-7351827-B2 | Substituted oxetanes, method of making, and method of use thereof | THE UNIVERSITY OF CONNECTICUT (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351827-B2 | Substituted oxetanes, method of making, and method of use thereof | THE UNIVERSITY OF CONNECTICUT (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351827-B2 | Substituted oxetanes, method of making, and method of use thereof | THE UNIVERSITY OF CONNECTICUT (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1685127-A1 | HETEROCYCLYL-SUBSTITUTED OXETANES FOR THE TREATMENT OF PROLIFERATIVE OR INFECTIOUS DISEASES | The University of Connecticut (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050215568-A1 | Substituted oxetanes, method of making, and method of use thereof | UNIVERSITY OF CONNECTICUT, THE | 2005-09-29 | — | — | US | disclosed |
| WO-2005051944-A1 | HETEROCYCLYL-SUBSTITUTED OXETANES FOR THE TREATMENT OF PROLIFERATIVE OR INFECTIOUS DISEASES | UNIVERSITY OF CONNECTICUT (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139566-A1 | SUBSTITUTED OXETANES, METHOD OF MAKING, AND METHOD OF USE THEREOF | PNP, TYMP, DHPS | TSHR 4430/4885KDM1A 3502/4885MAOA 982/4885 |
| US-20050215568-A1 | Substituted oxetanes, method of making, and method of use thereof | PNP, TYMP, DHPS | TSHR 4430/4885KDM1A 3502/4885MAOA 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.